Jaguar health reports first quarter 2024 financial results

The combined net q1 2024 revenue of approximately $2.4 million for prescription and non-prescription products increased approximately 20% versus net q1 2023 revenue of $2.0 million and increased approximately 4% versus net q4 2023 revenue of $2.3 million top line results expected to be imminent for company's phase 3 ontarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea jaguar planning to begin commercial launch in q3 2024 for gelclair®, the company's third prescription product reminder: jaguar to host investor webcast tuesday, may 14th at 8:30 a.m. eastern regarding q1 2024 financials and company updates; click here to register for webcast san francisco, ca / accesswire / may 14, 2024 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today reported consolidated first-quarter 2024 financial results and provided company updates.
JAGX Ratings Summary
JAGX Quant Ranking